INT211488

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 2007
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 5
Total Number 6
Disease Relevance 3.72
Pain Relevance 0.83

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (VEGFA) growth (VEGFA) extracellular region (VEGFA)
proteinaceous extracellular matrix (VEGFA) cytoplasm (VEGFA)
Anatomy Link Frequency
muscle tissues 2
fat 1
tail vein 1
VEGFA (Homo sapiens)
Pain Link Frequency Relevance Heat
Glutamate 148 97.80 Very High Very High Very High
Analgesic 1 85.88 High High
ischemia 16 74.44 Quite High
metalloproteinase 6 46.52 Quite Low
Kinase C 2 46.36 Quite Low
dysesthesia 1 36.16 Quite Low
cytokine 11 20.84 Low Low
Glutamate receptor 10 12.16 Low Low
excitatory amino acid 16 5.00 Very Low Very Low Very Low
antagonist 13 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Hypertension 81 95.20 Very High Very High Very High
Glaucoma 28 93.60 High High
Cancer 46 92.24 High High
Drug Induced Neurotoxicity 15 91.40 High High
Disease 31 86.76 High High
Diabetes Mellitus 61 84.76 Quite High
Renal Cancer 63 84.40 Quite High
Toxicity 57 78.00 Quite High
Cv Unclassified Under Development 12 74.44 Quite High
Proteinuria 11 69.76 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Introduction of homodimerized sVEGFR1 and lymphatic drainage did not drastically alter VEGF ligand and receptor distributions in healthy muscle tissues
Neg (not) Regulation (alter) of VEGF Binding (ligand) of in muscle tissues
1) Confidence 0.43 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0.05 Pain Relevance 0
HEK293 s cells that were transfected with VEGFR2 V297I SNP had significantly low VEGF binding efficiency regardless of VEGFR2 H472Q genotype, while variant VEGFR2 H472Q allele had minimal effect on VEGF binding efficiency [10].
Regulation (effect) of VEGF Binding (binding) of
2) Confidence 0.30 Published 2010 Journal J Exp Clin Cancer Res Section Body Doc Link PMC2913951 Disease Relevance 0.63 Pain Relevance 0
On the day of fat injection, 18 days after the fat injection, and at the end of the study period, each mouse was weighed, and a tail vein blood sample was collected for determining the red blood cell, leukocyte, and platelet counts, the plasma hemoglobin, VEGF, and EPO concentrations.
Regulation (collected) of VEGF in tail vein Spec (determining) Binding (determining) of in fat
3) Confidence 0.21 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2981551 Disease Relevance 0 Pain Relevance 0.09
Bevacizumab leads to rapid clearance of circulating VEGF, but is not known to affect VEGF bound to receptor, as the epitope on VEGF recognized by bevacizumab is in the VEGF-R binding region.
Regulation (affect) of VEGF Binding (bound) of
4) Confidence 0.20 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004565 Disease Relevance 1.00 Pain Relevance 0
important factors, for instance nitric oxide and VEGF, have to be
Regulation (be) of VEGF Binding (oxide) of
5) Confidence 0.07 Published 2007 Journal Experimental Diabetes Research Section Body Doc Link PMC1940058 Disease Relevance 1.02 Pain Relevance 0.37
important factors, for instance nitric oxide and VEGF, have to be
Regulation (have) of VEGF Binding (oxide) of
6) Confidence 0.07 Published 2007 Journal Experimental Diabetes Research Section Body Doc Link PMC1940058 Disease Relevance 1.02 Pain Relevance 0.37

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox